Clinical Trials Browser

ibrutinib × Classical hematology × Clear all

NCT02048813 2025-11-28

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Active not recruiting

529 enrolled 12 charts 2 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Phase 1 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT05694312 2023-12-01

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Phase 2 Recruiting

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell